Novo Nordisk signed an agreement with biotech company Vivtex to develop new oral drugs to treat obesity and diabetes.[2] Vivtex is a company co-founded by MIT professor Robert Langer, known for his contributions to biotechnology.[2] This partnership represents an expansion of Novo Nordisk's efforts in the field of metabolic disorders and obesity.[2] Novo Nordisk has long focused on the development of innovative medicines for the treatment of diabetes, obesity and other serious chronic diseases.[5] The company is currently working on a portfolio of drugs targeting various therapeutic areas, including cardiovascular disease and rare blood disorders.[5] This agreement with Vivtex continues Novo Nordisk's strategy to expand its research and development potential in the field of metabolic diseases.